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A gene coding for human Vale-calcitonin (Vals-hCT) was synthesized by the solid-phase phosphite approach 
and fused to a synthetic human immune interferon-y (IFN-y) gene. The IFN gene was previously shown 
to be expressed at a very high level in E. coli [(1986) Gene, in press] due to the control of a strong synthetic 
promoter and strong ribosome binding site. The cells harboring the fused gene produced 100-150 pg per 
1 of bacterial suspension of immunoreactive calcitonin in the form of hybrid IFN-y-Vale-hCT protein con- 
sisting of 140 amino acids. The VaP-hCT can be released from this protein by CNBr treatment. 
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1. INTRODUCTION 
Calcitonin (CT) is a 32 amino acid polypeptide 
secreted by the parafollicular cells of the thyroid in 
mammals. It plays an important homeostatic role 
by controlling calcium and phosphorus turnover. 
The main function of CT however, seems to be the 
protection of the skeleton against resorption dur- 
ing times of physiological stress uch as pregnancy, 
lactation and growth [1,2]. CT has proven to be 
very effective in the treatment of various kinds of 
diseases, such as Paget’s disease, osteoporosis im- 
perfecta, postmenopausal osteoporosis, and bone 
metastases. [For details see Proc. Int. Symp. 
Calcitonin 1980 and 1984, Milan (Pecile, A. ed.) 
Elsevier.] CT exhibits low species specificity and 
this characteristic has made it possible to use 
animal CT (salmon, eel and porcine) for treatment 
of human patients in the absence of the availability 
of human CT (hCT). The species variations in the 
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structure of these CTs however result in antibody 
formation upon repeated administration [3-71. 
Since 1968 synthetic hCT has become available 
[8,9] but its activity appears to be inferior when 
compared with those of the natural preparations 
[lO,ll]. 
The shortcomings outlined above of the CTs 
currently available for clinical use give momentum 
to the search for alternative approaches for prepar- 
ing hCT for clinical applications. Recently, hCT 
genes coding for either Val*-hCT [ 121 or Met*-hCT 
[ 131 have been synthesized and expressed in E. cob. 
The Val*-hCG gene has been fused to the gene of 
P-galactosidase [12] whereas the Met*-hCT gene 
was expressed directly under a strong promoter 
and a strong synthetic ribosomal binding site 
(RBS) [ 131. In both cases a low level of expression 
(low protein content) has been recorded. 
Here we report the results on the chemical syn- 
thesis and expression in E. coli of another hCT 
gene coding for Val*-hCT by fusing it to a syn- 
thetic IFN-7 gene which is expressed at a very high 
level and is under the control of a strong synthetic 
promoter and strong synthetic RBS [14]. 
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2. MATERIALS AND METHODS gene was verified after cloning by the method of 
Maxam and Gilbert [16]. 
2.1. Chemical synthesis, purification and 
phosphorylation of oligonucleotides 2.5. RNA dot hybridization 
All oligonucleotide fragments were synthesized 
by a modified solid-phase phosphite method as in 
[ 151. The synthetic oligonucleotides were purified 
by HPLC on a lOSAX anion-exchange column. 
The high yield of the synthesis (40-60%) made it 
possible to avoid further purification on a second 
reversed-phase column. The purified and desalted 
oligonucleotides were phosphorylated at the 
5’-terminus with [y-3ZP]ATP (5-10 Ci/mmol) and 
T4 polynucleotide kinase. The labelled oligonu- 
cleotides were purified on a 2Oqo polyacrylamide 
sequencing el. 
2.2. Ligation and purification of the Vaa-hCT 
gene 
The phosphorylated oligonucleotides of 5 pmol 
aliquots each (except for the terminal fragments in 
which 8 pmol were used) were mixed in 40 pl of 
100 mM Tris, pH 7.5/20 mM MgClz, heated to 
90°C and slowly cooled to 12.5”C. The mixture 
was then adjusted to 50 mM Tris, pH 7.5110 mM 
MgClz/lO mM dithiothreitol/l mM ATP and 
10 U of T4 DNA ligase. The ligation reaction was 
carried out at 12.5”C for 16 h. The T4 DNA ligase 
was inactivated at 70°C for 10 min, Bg/II (10 
units) added and the incubation continued over- 
night at 37°C. The reaction mixture was loaded on 
an 8% polyacrylamide gel (4 V/cm for 8 h) and 
the Val’-hCT gene visualized by autoradiography 
and recovered as in [15]. 
2.3. Cloning of Val8-hCT gene into 
~JPIR~--IFN--~ expression vector 
The purified Val’-hCT gene containing two ter- 
minal Bg/II sites was ligated using standard condi- 
tions to a 4-fold excess of pJPiRg-IFN-y pretreated 
with BgfiI and calf intestinal alkaline phosphatase. 
The ligation mixture was used to transform compe- 
tent cells (ZZ. coli LE392). Recombinant clones 
were selected by colony hybridization using 32P- 
labelled synthetic oligonucleotides as specific 
probes. 
To detect he clones with the CT gene in the cor- 
rect orientation, and under the control of the 
transcription unit of the IFN gene, total cell RNA 
was isolated from 14 different clones selected by 
colony hybridization and probed with (5-32P)- 
labelled synthetic oligonucleotides of the non- 
coding DNA strand of the CT gene. RNA was 
prepared from 1.5 A590 units of recombinant 
bacteria grown in LB containing lOpg/ml 
tetracycline at 37°C to Aw, = 2.0. The cells were 
pelleted and lysed in 300~1 of 300 mM sodium 
acetate, pH 6.2/l% SDS. An equal volume of 
phenol was added and the mixture heated for 
10 min at 65°C. The aqueous phase was further 
deproteinized and mixed with 3 vols ethanol. The 
precipitate was dissolved in 200 pl of 50 mM Tris, 
pH 7.4/10 mM MgClz, treated with lOpg/ml 
DNase I (RNase-free), deproteinized as above and 
precipitated with ethanol. RNA was dissolved in 
50~1 of 3 x SSC/lO% formaldehyde, heated at 
65°C for 10 min and dotted onto two 
nitrocellulose filters. Each sample was loaded 
separately as two aliquots (6 and 18 ~1, respective- 
ly). The filters were dried in a vacuum oven for 
15 min at 8O”C, prehybridized in 1 M NaC1/0.2% 
SDS/100 mM Tris, pH 7.0/100 pg/ml homomix I 
(a partial alkaline hydrolysate of yeast tRNA) [24] 
for 2 h at 60°C. Hybridization was carried out in 
10 ml of the same solution containing 2-5 x 
10’ cpm of end-labelled oligonucleotide at 42°C 
for 2 h. The filters were washed with 1 M 
NaC1/0.2% SDS twice for 15 min at the 
temperature of incubation and once at 50°C for 
15 min. 
2.6. Radioimmunoassay and protein analysis 
Goat hCT antibodies and standard synthetic 
hCT were purchased from Milab (Sweden) and the 
RIA test was carried out as recommended by the 
producer. 
2.4. Sequence anaiysis of DNA cloned in 
pJPrRs--IFN-y vector 
The primary structure of the synthetic Val*-hCT 
Total bacterial protein was analysed by Laemmli 
[17] electrophoresis. For this purpose 2 A590 units 
of recombinant cells were harvested and lysed in 
200~1 of 50 mM Tris, pH 6.8/2% SDS/2070 ,& 
mercaptoethanol/lO% glycerol/O.01 070 bromo- 
phenol blue in a boiling water bath for 5 min. 
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Samples of 5-15 ~1 were loaded on a 15% 
polyacrylamide gel. 
3. RESULTS AND DISCUSSION 
Manufacturing of eukaryotic, biologically active 
peptides of low A4, by the recombinant DNA ap- 
proach is still not a trivial task for genetic engineer- 
ing. The low-M, proteins are presumably 
recognized as foreign substances and are usually 
degraded extensively by the bacterial cell [18,19]. 
To study the stability of recombinant hCT 
against proteolysis in bacteria we have constructed 
and expressed in E. coli a series of synthetic genes 
coding for hCT in either monomeric or multimeric 
form. It was found that the hCT is stable in E. coli 
cells when synthesized as a tetramer or larger, i.e. 
when the polypeptide chain has increased to 132 
amino acids in length [20]. These results encour- 
aged us to construct a hybrid IFN-y-hCT gene 
coding for a protein of approximately the same 
molecular size. The gene of IFN-7 was chosen for 
this construction since this gene was recently syn- 
thesized and expressed (under the strong synthetic 
promoter PI and the strong synthetic RBS RJ) in E. 
coli at a very high level (> 15 070 of the total cell pro- 
tein), confirming its compatibility with the E. co/i 
cell [14,15]. Our experiments on the direct expres- 
sion (without fusion) of monomeric and 
multimeric hCT genes in E. coli under the same ex- 
pression system resulted in a low yield (as com- 
pared with that of IFN-7) and inhibition of cell 
growth [20]. Taking into account these observa- 
tions, it would be interesting to determine whether 
the fusion of the hCT gene to the IFN-y gene 
would favor both the expression of the hybrid CT 
protein and the normal growth of the recombinant 
bacteria. 
To construct the fused gene an hCT gene was 
synthesized as designated in fig.1. This gene is 
composed of 16 oligonucleotides (underlined in the 
figure) comprising both strands of the synthetic 
DNA. The gene codes for 33 amino acids (32 cor- 
responding to the mature CT molecule plus one ad- 
ditional terminal methionine). The nucleotide 
sequence of the synthetic gene was derived from 
the structure of the human pre-CT mRNA as 
determined by Craig et al. [21] except hat the Val’ 
codon was substituted for the native Met* codon. 
This substitution was necessary to obtain an hCT 
free of methionine in order to treat the hybrid pro- 
tein with CNBr to provide the Val’-hCT. The 
following arguments were taken into account when 
designing this substitution: (i) most of the animal 
CTs contain Val’ instead of Met’ [2] and are both 
more active and more stable (since Met tends to be 
oxidized) [22]; (ii) the Va18 substitution should not 
change the antigenic properties of the CT molecule 
since only the amino acids between 11 and 32 are 
responsible for the antigenicity of CT [23]. 
The synthetic Val”-hCT gene is flanked by two 
BgflI sites. Its 5 ‘-end is constructed such that its 
coding sequence is in the same reading frame as 
that of the IFN-7 gene in the fused gene (see fig.2). 
The principle scheme for cloning of the Va18-hCT 
gene into the expression plasmid pJP,R9-IFN is 
shown in fig.3. This plasmid has a unique BgfII site 
located between amino acids 105 and 106 of the 
IFN-7 gene (the N-terminal Met not included). 
Upon insertion of the hCT gene the last 40 codons 
of the IFN-y gene (of the total 147 codons) are 
switched off from translation and 33 new CT 
codons are added. Since the insertion of the 
Va18-hCT gene is possible in two orientations, 
recombinant clones containing the gene in the cor- 
rect orientation had to be identified. As seen in 
fig.1, the synthetic gene is devoid of any ap- 
propriate restriction endonuclease sites and 
therefore restriction analysis cannot be applied to 
test for the gene’s orientation. Because of that we 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 
MetCysGlyAsnLeuSerThrCysValLeuGlyThrTyrThrGlnAspPheAsnLysPheH~sThrPheProGlnThrAlaIleGlyValGlyAlaPro 
1 3 5 7 9 11 13 15 
IIIIIIrnIIII' 
GATCTGATGTGCGGTAATCTGAGTACTTGCGTGCTGGGCACATACACGCAGGACTTCAACAAGTTTCACACGTTCCCCCAAACTGCAATTGGGGTTGGAGCACCTTAA 
ACTACACGCCATTAGACTCATGAACGTACGACCCGTGTATGTGCGTCCTGAAGTTGTTCAAAGTGTGCAAGGGGGTTTGACGTTAACCCCAACCTCGTGGAATTCTAG 
-IIII-IIItlIII 
2 4 6 8 10 12 14 16 
Bgl II Bgl II 
Fig.1. Nucleotide sequence of the synthetic Val*-hCT gene. 
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IF-gamma hCT 
103 101 903 101 I 2 
ValThrlspLeuYetCysCly 
. . . . . GTAACPr;_A_T_GATGTGCGGT..... 
. . . . . CATTGTCTAkTACACGCCA..... 
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A 
Fig.2. Cloning of the synthetic Val’-hCT gene in 
pJPrR9-IFN-y expression plasmid. 
selected clones with the hCT in the correct orienta- 
tion by RNA-oligonucleotide hybridization. Total 
cell RNA was hybridized with labelled synthetic 
oligonucleotides belonging either to the coding 
(fig.4B) or to the opposite (fig.4A), non-coding 
strand of the gene. Only those clones giving a 
positive signal with gene fragment nos 2 and 6 
(fig.4B) and a negative signal with oligonucleotide 
no. 15 (fig.4A) were used in subsequent ex- 
periments. 
The efficiency of transcription of the fused 
Val*-hCT gene was tested using the same 
hybridization procedure described above and it 
was found that the maximum accumulation of CT 
mRNA in the E. coli cells occurred when the densi- 
ty of the bacterial suspension reached 1.7-2.0 
Asso. 
The efficiency of translation of the hybrid gene 
was studied both by gel analysis according to 
Laemmli [17] and by RIA testing. Our results 
IF -gamma 
-Bgl II 
Bgl II BRl II 
hCT 
IF -gamma 
- Bgl II 
hCT 
Bgl II 
Fig.3. The site of fusion between the two synthetic 
genes. 
5 
12 3 4 
6 
11 
7 
12 
8 
B 
5 
Fig.4. Screening for clones harboring the Val’-hCT gene 
in the correct orientation. Total cell RNA was isolated as 
described in section 2 and dotted onto two nitrocellulose 
filters. Filter A was hybridized with oligonucleotide 
no. 15 (as marked in fig. 1) and filter B with a mixture of 
oligonucleotide nos 2 and 6. 
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clearly showed that the fusion of the Va18-hCT 
gene to the gene of IFN-7 led to a dramatic 
decrease in translational efficiency. The yield of 
the hybrid protein was below 1% of the total cell 
protein (vs 15% for the IFN-7 gene) as judged by 
SDS electrophoresis method. This decrease cannot 
be due to a change in the initiation of translation, 
but results from either a decrease in the stability of 
the hybrid protein or the hybrid in mRNA. 
The immunoreactive recombinant hCT was 
quantitated by RIA and a value of about 
100-150 pg CT per 1 of bacterial culture (at a cell 
density of 1.7-2.0 A590) was registered. This value 
however might be underestimated since the recom- 
binant hCT is not amidated, whereas the an- 
tibodies used for RIA have been prepared against 
synthetic amidated hCT. 
When cultivating recombinant bacteria harbor- 
ing the IFN-y-Va18-hCT gene, it was also found 
that they grew more slowly than the host cells or 
cells carrying the IFN-y gene only. However, they 
grew better than the cells expressing hCT gene(s) 
directly (without fusion). Based on these observa- 
tions and keeping in mind the hydrophobic 
character of hCT, one might propose that the cell 
growth inhibition (and probably the poor expres- 
sion as well) is due to some interaction between CT 
and the inner surface of the cell membrane. This 
offers an interesting model for studying the effects 
of amino acid substitutions on the stability of 
heterologous proteins in bacteria and their effect 
on bacterial cell functioning in addition to that on 
the activity of the modified calcitonin protein. 
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